Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) saw unusually-strong trading volume on Tuesday . Approximately 1,716,302 shares were traded during trading, an increase of 100% from the previous session’s volume of 856,780 shares.The stock last traded at $4.77 and had previously closed at $4.43.

A number of equities analysts have weighed in on PGNX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Progenics Pharmaceuticals in a research note on Monday, March 14th. Brean Capital reiterated a “buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a report on Tuesday, March 15th. BTIG Research cut their price target on shares of Progenics Pharmaceuticals from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, March 15th. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Finally, Jefferies Group reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a report on Friday, June 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $10.35.

The stock has a 50 day moving average of $4.70 and a 200 day moving average of $4.74. The company’s market cap is $360.57 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.05. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $3.27 million. The business’s quarterly revenue was up 908.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.15) EPS. On average, equities analysts expect that Progenics Pharmaceuticals Inc. will post $0.12 EPS for the current fiscal year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.